FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

REGISTER

now for free

Melinda Hollingshead

Research Profile

Living Beings

Chemicals & Drugs

Anatomy

Procedures

Disorders

Neoplasms

Physiology

Concepts & Ideas

Structure-Activity Relationship

Register to see full profile

Co-author Network

Register to see all co-authors

Publications

TOP 3
Susan D Mertins; Anne Monks; David S Salomon; Dominic A Scudiero; Michael C Alley; David G Covell; Raymond D Divelbiss; Karen Hite; Melinda G Hollingshead; John E Niederhuber
A small molecule (pluripotin) as a tool for studying cancer stem cell biology: proof of concept.
Thomas D Pfister; Yves Pommier; Howard Stotler; Joseph E Tomaszewski; Yiping Zhang; Suzanne D Borgel; John Carter; Raymond Divelbiss; Yvonne A Evrard; Melinda G Hollingshead; Jiuping Ji; Sonny A Khin; Robert Kinders; Shivaani Kummar; Ralph E Parchment; James H Doroshow
Development and validation of an immunoassay for quantification of topoisomerase I in solid tumor tissues.
Vaibhav Saini; Dominic A Scudiero; Jalpa Shah; Thomas E Silvers; Mark W Burkett; Rene M Delosh; Bingnan Han; Karen Hite; Melinda G Hollingshead; Curtis Hose; Angelena Millione; Anne Monks; Kunio Nagashima; Dianne L Newton; Robert H Shoemaker
Identification of CBX3 and ABCA5 as putative biomarkers for tumor stem cells in osteosarcoma.

Register to see all publications

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Register to see more

Geonetwork of Melinda Hollingshead (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Register to see more

All Publications

2013: Susan D Mertins; Anne Monks; David S Salomon; Dominic A Scudiero; Michael C Alley; David G Covell; Raymond D Divelbiss; Karen Hite; Melinda G Hollingshead; John E Niederhuber
A small molecule (pluripotin) as a tool for studying cancer stem cell biology: proof of concept.
PloS one 2013;8(2):e57099.
2012: Thomas D Pfister; Yves Pommier; Howard Stotler; Joseph E Tomaszewski; Yiping Zhang; Suzanne D Borgel; John Carter; Raymond Divelbiss; Yvonne A Evrard; Melinda G Hollingshead; Jiuping Ji; Sonny A Khin; Robert Kinders; Shivaani Kummar; Ralph E Parchment; James H Doroshow
Development and validation of an immunoassay for quantification of topoisomerase I in solid tumor tissues.
PloS one 2012;7(12):e50494.
2012: Vaibhav Saini; Dominic A Scudiero; Jalpa Shah; Thomas E Silvers; Mark W Burkett; Rene M Delosh; Bingnan Han; Karen Hite; Melinda G Hollingshead; Curtis Hose; Angelena Millione; Anne Monks; Kunio Nagashima; Dianne L Newton; Robert H Shoemaker
Identification of CBX3 and ABCA5 as putative biomarkers for tumor stem cells in osteosarcoma.
PloS one 2012;7(8):e41401.
2012: Chi-Ping Day; Melinda G Hollingshead; Carrie A Bonomi; John Carter; Glenn Merlino
Preclinical therapeutic response of residual metastatic disease is distinct from its primary tumor of origin.
International journal of cancer. Journal international du cancer 2012;130(1):190-9.
2011: Shivaani Kummar; Giovanni Melillo; Anthony J Murgo; Ralph E Parchment; Yves Pommier; Joel M Reid; Larry Rubinstein; Giovanna Speranza; Howard Stotler; Joseph E Tomaszewski; Lihua Wang; Marcie Weil; Yiping Zhang; Matthew Ames; William Bonner; John Carter; Alice Chen; Melinda G Hollingshead; Jiuping Ji; Lee Jia; Robert Kinders; James H Doroshow
Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas.
Cancer research 2011;71(17):5626-34.
2011: Susan Kenney; David S Schrump; Luke H Stockwin; David T Vistica; Suzanne D Borgel; Sandra Burkett; Donna O Butcher; Melinda G Hollingshead; Robert H Shoemaker
ASPS-1, a novel cell line manifesting key features of alveolar soft part sarcoma.
Journal of pediatric hematology/oncology 2011;33(5):360-8.
2011: Sergio Y Alcoser; Suzanne D Borgel; John P Carter; Kelly M Dougherty; David J Kimmel; Melinda G Hollingshead
Real-time PCR-based assay to quantify the relative amount of human and mouse tissue present in tumor xenografts.
BMC biotechnology 2011;11():124.
2011: Chad N Hancock; Luke H Stockwin; Bingnan Han; Raymond D Divelbiss; Jung Ho Jun; Sanjay V Malhotra; Melinda G Hollingshead; Dianne L Newton
A copper chelate of thiosemicarbazone NSC 689534 induces oxidative/ER stress and inhibits tumor growth in vitro and in vivo.
Free radical biology & medicine 2011;50(1):110-21.
2010: Luke H Stockwin; Sherry X Yu; Suzanne Borgel; Chad Hancock; Tracy L Wolfe; Lawrence R Phillips; Melinda G Hollingshead; Dianne L Newton
Sodium dichloroacetate selectively targets cells with defects in the mitochondrial ETC.
International journal of cancer. Journal international du cancer 2010;127(11):2510-9.
2010: Robert Kinders; Melinda G Hollingshead; Scott Lawrence; Jiuping Ji; Brian Tabb; William M Bonner; Yves Pommier; Larry Rubinstein; Yvonne A Evrard; Ralph E Parchment; Joseph Tomaszewski; James Doroshow
Development of a validated immunofluorescence assay for γH2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(22):5447-57.
2010: Bingnan Han; Luke H Stockwin; Chad Hancock; Sherry X Yu; Melinda G Hollingshead; Dianne L Newton
Proteomic analysis of nuclei isolated from cancer cell lines treated with indenoisoquinoline NSC 724998, a novel topoisomerase I inhibitor.
Journal of proteome research 2010;9(8):4016-27.
2009: Luke H Stockwin; Bingnan Han; Sherry X Yu; Melinda G Hollingshead; Mahmoud A ElSohly; Waseem Gul; Desmond Slade; Ahmed M Galal; Dianne L Newton; Maja A Bumke
Artemisinin dimer anticancer activity correlates with heme-catalyzed reactive oxygen species generation and endoplasmic reticulum stress induction.
International journal of cancer. Journal international du cancer 2009;125(6):1266-75.
2009: David T Vistica; Melinda G Hollingshead; Suzanne D Borgel; Susan Kenney; Luke H Stockwin; Mark Raffeld; David S Schrump; Sandra Burkett; Gary Stone; Donna O Butcher; Robert H Shoemaker
Therapeutic vulnerability of an in vivo model of alveolar soft part sarcoma (ASPS) to antiangiogenic therapy.
Journal of pediatric hematology/oncology 2009;31(8):561-70.
2009: Annamaria Rapisarda; Melinda G Hollingshead; Badarch Uranchimeg; Carrie A Bonomi; Suzanne D Borgel; John P Carter; Bradley Gehrs; Mark Raffeld; Robert Kinders; Ralph Parchment; Miriam R Anver; Robert H Shoemaker; Giovanni Melillo
Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition.
Molecular cancer therapeutics 2009;8(7):1867-77.
2009: Ahmed M Galal; Waseem Gul; Desmond Slade; Samir A Ross; Shixia Feng; Melinda G Hollingshead; Michael C Alley; Gurmeet Kaur; Mahmoud A ElSohly
Synthesis and evaluation of dihydroartemisinin and dihydroartemisitene acetal dimers showing anticancer and antiprotozoal activity.
Bioorganic & medicinal chemistry 2009;17(2):741-51.
2009: Luke H Stockwin; Sherry X Yu; Howard Stotler; Melinda G Hollingshead; Dianne L Newton
ARC (NSC 188491) has identical activity to Sangivamycin (NSC 65346) including inhibition of both P-TEFb and PKC.
BMC cancer 2009;9():63.
2008: Melinda G Hollingshead
Antitumor efficacy testing in rodents.
Journal of the National Cancer Institute 2008;100(21):1500-10.
2008: Robert Kinders; Melinda G Hollingshead; Sonny Khin; Larry Rubinstein; Joseph E Tomaszewski; James Doroshow; Ralph E Parchment
Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP-ribose) polymerase in tumor biopsies of mouse xenografts.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(21):6877-85.
2008: Anthony J Murgo; Shivaani Kummar; Larry Rubinstein; Martin Gutierrez; Jerry Collins; Robert Kinders; Ralph E Parchment; Jiuping Ji; Seth M Steinberg; Sherry X Yang; Melinda G Hollingshead; Alice Chen; Lee Helman; Robert Wiltrout; Joseph E Tomaszewski; James Doroshow
Designing phase 0 cancer clinical trials.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(12):3675-82.
2008: Shivaani Kummar; Larry Rubinstein; Robert Kinders; Ralph E Parchment; Martin E Gutierrez; Anthony J Murgo; Jay Ji; Barbara Mroczkowski; Oxana Pickeral; Mel Simpson; Melinda G Hollingshead; Sherry X Yang; Lee Helman; Robert Wiltrout; Jerry Collins; Joseph E Tomaszewski; James Doroshow
Phase 0 clinical trials: conceptions and misconceptions.
Cancer journal (Sudbury, Mass.) 2008;14(3):133-7.
2008: Regan M Memmott; Joell J Gills; Melinda G Hollingshead; Margaret C Powers; Zhiping Chen; Bruce Kemp; Alan P Kozikowski; Phillip A Dennis
Phosphatidylinositol ether lipid analogues induce AMP-activated protein kinase-dependent death in LKB1-mutant non small cell lung cancer cells.
Cancer research 2008;68(2):580-8.
2008: Mollie H Wright; Ana I Robles; Jason Herschkowitz; Melinda G Hollingshead; Miriam R Anver; Charles M Perou; Lyuba Varticovski
Molecular analysis reveals heterogeneity of mouse mammary tumors conditionally mutant for Brca1.
Molecular cancer 2008;7():29.
2007: Robert Kinders; Ralph E Parchment; Jay Ji; Shivaani Kummar; Anthony J Murgo; Martin Gutierrez; Jerry Collins; Larry Rubinstein; Oxana Pickeral; Seth M Steinberg; Sherry Yang; Melinda G Hollingshead; Alice Chen; Lee Helman; Robert Wiltrout; Mel Simpson; Joseph E Tomaszewski; James Doroshow
Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.
Molecular interventions 2007;7(6):325-34.
2007: Joell J Gills; S Sianna Castillo; Chunyu Zhang; Pavel A Petukhov; Regan M Memmott; Melinda G Hollingshead; Noel A Warfel; Jiahuai Han; Alan P Kozikowski; Phillip A Dennis
Phosphatidylinositol ether lipid analogues that inhibit AKT also independently activate the stress kinase, p38alpha, through MKK3/6-independent and -dependent mechanisms.
The Journal of biological chemistry 2007;282(37):27020-9.
2007: Maria V Papadopoulou; William D Bloomer; Alice P Taylor; Marisol Hernandez; Rosalyn D Blumenthal; Melinda G Hollingshead
Advantage of combining NLCQ-1 (NSC 709257) with radiation in treatment of human head and neck xenografts.
Radiation research 2007;168(1):65-71.
2007: Luke H Stockwin; Maja A Bumke; Sherry X Yu; Simon P Webb; Jack R Collins; Melinda G Hollingshead; Dianne L Newton
Proteomic analysis identifies oxidative stress induction by adaphostin.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(12):3667-81.
2007: Lyuba Varticovski; Melinda G Hollingshead; Ana I Robles; Xiaolin Wu; James Cherry; David J Munroe; Luanne Lukes; Miriam R Anver; John P Carter; Suzanne D Borgel; Howard Stotler; Carrie A Bonomi; Nomeli P Nunez; Stephen D Hursting; Wenhui Qiao; Chuxia X Deng; Jeffrey E Green; Kent W Hunter; Glenn Merlino; Patricia S Steeg; Lalage M Wakefield; J Carl Barrett
Accelerated preclinical testing using transplanted tumors from genetically engineered mouse breast cancer models.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(7):2168-77.
2006: Muthukaman Nagarajan; Andrew Morrell; Alexandra Ioanoviciu; Smitha Antony; Glenda Kohlhagen; Keli Agama; Melinda G Hollingshead; Yves Pommier; Mark Cushman
Synthesis and evaluation of indenoisoquinoline topoisomerase I inhibitors substituted with nitrogen heterocycles.
Journal of medicinal chemistry 2006;49(21):6283-9.
2006: Smitha Antony; Keli Agama; Ze-Hong Miao; Melinda G Hollingshead; Susan Holbeck; Mollie H Wright; Lyuba Varticovski; Muthukaman Nagarajan; Andrew Morrell; Mark Cushman; Yves Pommier
Bisindenoisoquinoline bis-1,3-{(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline)-6-propylamino}propane bis(trifluoroacetate) (NSC 727357), a DNA intercalator and topoisomerase inhibitor with antitumor activity.
Molecular pharmacology 2006;70(3):1109-20.
2006: Muthukaman Nagarajan; Andrew Morrell; Smitha Antony; Glenda Kohlhagen; Keli Agama; Yves Pommier; Patricia A Ragazzon; Nichola C Garbett; Jonathan B Chaires; Melinda G Hollingshead; Mark Cushman
Synthesis and biological evaluation of bisindenoisoquinolines as topoisomerase I inhibitors.
Journal of medicinal chemistry 2006;49(17):5129-40.
2006: Andrew Morrell; Muthusamy Jayaraman; Muthukaman Nagarajan; Brian M Fox; Marintha Rae Meckley; Alexandra Ioanoviciu; Yves Pommier; Smitha Antony; Melinda G Hollingshead; Mark Cushman
Evaluation of indenoisoquinoline topoisomerase I inhibitors using a hollow fiber assay.
Bioorganic & medicinal chemistry letters 2006;16(16):4395-9.
2006: Jeanelle M Martinez; Tina Sali; Ryuji Okazaki; Colleen H Anna; Melinda G Hollingshead; Curtis Hose; Anne Monks; Nigel J Walker; Seung Joon Baek; Thomas E Eling
Drug-induced expression of nonsteroidal anti-inflammatory drug-activated gene/macrophage inhibitory cytokine-1/prostate-derived factor, a putative tumor suppressor, inhibits tumor growth.
The Journal of pharmacology and experimental therapeutics 2006;318(2):899-906.
2006: Lorena de la Peña; William E Burgan; Donna J Carter; Melinda G Hollingshead; Merriline Satyamitra; Kevin A Camphausen; Philip J Tofilon
Inhibition of Akt by the alkylphospholipid perifosine does not enhance the radiosensitivity of human glioma cells.
Molecular cancer therapeutics 2006;5(6):1504-10.
2006: Gurmeet Kaur; Melinda G Hollingshead; Susan Holbeck; Vesna Schauer-Vukasinović; Richard F Camalier; Alexander Dömling; Seema Agarwal
Biological evaluation of tubulysin A: a potential anticancer and antiangiogenic natural product.
The Biochemical journal 2006;396(2):235-42.
2006: Christopher Barker; William E Burgan; Donna J Carter; David Cerna; David Gius; Melinda G Hollingshead; Kevin A Camphausen; Philip J Tofilon
In vitro and in vivo radiosensitization induced by the ribonucleotide reductase inhibitor Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone).
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(9):2912-8.
2006: Joell J Gills; Susan Holbeck; Melinda G Hollingshead; Stephen M Hewitt; Alan P Kozikowski; Phillip A Dennis
Spectrum of activity and molecular correlates of response to phosphatidylinositol ether lipid analogues, novel lipid-based inhibitors of Akt.
Molecular cancer therapeutics 2006;5(3):713-22.
2005: Melinda G Hollingshead; Michael Alley; Angelika Burger; Suzanne D Borgel; Christine Pacula-Cox; Heinz-Herbert Fiebig; Edward A Sausville
In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative.
Cancer chemotherapy and pharmacology 2005;56(2):115-25.
2005: Wieslaw Cholody; Teresa Kosakowska-Cholody; Melinda G Hollingshead; Humcha K Hariprakasha; Christopher J Michejda
A new synthetic agent with potent but selective cytotoxic activity against cancer.
Journal of medicinal chemistry 2005;48(13):4474-81.
2005: Hideaki Dote; David Cerna; William E Burgan; Donna J Carter; Michael A Cerra; Melinda G Hollingshead; Kevin A Camphausen; Philip J Tofilon
Enhancement of in vitro and in vivo tumor cell radiosensitivity by the DNA methylation inhibitor zebularine.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(12):4571-9.
2005: Diane Palmieri; Douglas Halverson; Taoufik Ouatas; Christine E Horak; Massimiliano Salerno; Jennifer Johnson; W Douglas Figg; Melinda G Hollingshead; Stephen D Hursting; David Berrigan; Seth M Steinberg; Maria J Merino; Patricia S Steeg
Medroxyprogesterone acetate elevation of Nm23-H1 metastasis suppressor expression in hormone receptor-negative breast cancer.
Journal of the National Cancer Institute 2005;97(9):632-42.
2005: Maria V Papadopoulou; William D Bloomer; Melinda G Hollingshead
NLCQ-1 (NSC 709257) in combination with radiation against human glioma U251 xenografts.
Anticancer research 2005;25(3B):1865-9.
2005: Gurmeet Kaur; Ven L Narayanan; Prabhakar A Risbood; Melinda G Hollingshead; Sherman F Stinson; Ravi K Varma; Edward A Sausville
Synthesis, structure-activity relationship, and p210(bcr-abl) protein tyrosine kinase activity of novel AG 957 analogs.
Bioorganic & medicinal chemistry 2005;13(5):1749-61.
2004: Elizabeth E A Bull; Hideaki Dote; Kristin J Brady; William E Burgan; Donna J Carter; Michael A Cerra; Kelli A Oswald; Melinda G Hollingshead; Kevin A Camphausen; Philip J Tofilon
Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(23):8077-84.
2004: Miriam Gitler; Edward A Sausville; Melinda G Hollingshead; Robert Shoemaker
In vivo models for experimental therapeutics relevant to human cancer.
Cancer research 2004;64(22):8478-80.
2004: Annamaria Rapisarda; Jessica Zalek; Melinda G Hollingshead; Till Braunschweig; Badarch Uranchimeg; Carrie A Bonomi; Suzanne D Borgel; John P Carter; Stephen M Hewitt; Robert H Shoemaker; Giovanni Melillo
Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts.
Cancer research 2004;64(19):6845-8.
2004: Michael C Alley; Melinda G Hollingshead; Christine M Pacula-Cox; William R Waud; John A Hartley; Philip W Howard; Stephen J Gregson; David E Thurston; Edward A Sausville
SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 2: efficacy evaluations.
Cancer research 2004;64(18):6700-6.
2004: John A Hartley; Victoria J Spanswick; Natalie A Brooks; Peter H Clingen; Peter J McHugh; Daniel Hochhauser; R Barbara Pedley; Lloyd R Kelland; Michael C Alley; Robert Schultz; Melinda G Hollingshead; Karen M Schweikart; Joseph E Tomaszewski; Edward A Sausville; Stephen J Gregson; Philip W Howard; David E Thurston
SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity.
Cancer research 2004;64(18):6693-9.
2004: Gurmeet Kaur; Dorina Belotti; Angelika Burger; Kirsten Fisher-Nielson; Patrizia Borsotti; Elena Riccardi; Jagada Thillainathan; Melinda G Hollingshead; Edward A Sausville; Raffaella Giavazzi
Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(14):4813-21.
2004: Brian K Adams; Eva M Ferstl; Matthew C Davis; Marike Herold; Serdar Kurtkaya; Richard F Camalier; Melinda G Hollingshead; Gurmeet Kaur; Edward A Sausville; Frederick R Rickles; James P Snyder; Dennis C Liotta; Mamoru Shoji
Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents.
Bioorganic & medicinal chemistry 2004;12(14):3871-83.
2004: Andrea I Loaiza-Pérez; Susan Kenney; Jamie L Boswell; Melinda G Hollingshead; Michael C Alley; Curtis Hose; Henry P Ciolino; Grace Chao Yeh; Jane Trepel; David T Vistica; Edward A Sausville
Aryl hydrocarbon receptor activation of an antitumor aminoflavone: basis of selective toxicity for MCF-7 breast tumor cells.
Molecular cancer therapeutics 2004;3(6):715-25.
2004: Melinda G Hollingshead; Carrie A Bonomi; Suzanne D Borgel; John P Carter; R Shoemaker; Giovanni Melillo; Edward A Sausville
A potential role for imaging technology in anticancer efficacy evaluations.
European journal of cancer (Oxford, England : 1990) 2004;40(6):890-8.
2004: S Decker; Melinda G Hollingshead; Carrie A Bonomi; John P Carter; Edward A Sausville
The hollow fibre model in cancer drug screening: the NCI experience.
European journal of cancer (Oxford, England : 1990) 2004;40(6):821-6.
2004: Andrea I Loaiza-Pérez; S Kenney; Jamie L Boswell; Melinda G Hollingshead; Curtis Hose; W Marston Linehan; Robert Worrell; Lawrence V Rubinstein; Edward A Sausville; David T Vistica
Sensitivity of renal cell carcinoma to aminoflavone: role of CYP1A1.
The Journal of urology 2004;171(4):1688-97.
2003: Curtis Hose; Melinda G Hollingshead; Edward A Sausville; Anne Monks
Induction of CYP1A1 in tumor cells by the antitumor agent 2-[4-amino-3-methylphenyl]-5-fluoro-benzothiazole: a potential surrogate marker for patient sensitivity.
Molecular cancer therapeutics 2003;2(12):1265-72.
2003: Susanna M Rybak; Elena Sanovich; Melinda G Hollingshead; Suzanne D Borgel; Dianne L Newton; Giovanni Melillo; Dehe Kong; Gurmeet Kaur; Edward A Sausville
"Vasocrine" formation of tumor cell-lined vascular spaces: implications for rational design of antiangiogenic therapies.
Cancer research 2003;63(11):2812-9.
2002: Peter J Houghton; Peter Charles Adamson; Susan Blaney; Howard A Fine; Richard Gorlick; Michelle Haber; Lee Helman; Steve Hirschfeld; Melinda G Hollingshead; Mark Israel; Richard B Lock; John M Maris; Glenn Merlino; Wendy Patterson; Charles Patrick Reynolds; Kevin Shannon; Alice L Yu; John Yu; Malcolm A Smith
Testing of new agents in childhood cancer preclinical models: meeting summary.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(12):3646-57.
2002: Maria V Papadopoulou; Ming Ji; Xinhai Ji; William D Bloomer; Melinda G Hollingshead
Therapeutic advantage from combining paclitaxel with the hypoxia-selective cytotoxin NLCQ-1 in murine tumor- or human xenograft-bearing mice.
Cancer chemotherapy and pharmacology 2002;50(6):501-8.
2002: Mark Cushman; Arasambattu K Mohanakrishnan; Melinda G Hollingshead; Ernest Hamel
The effect of exchanging various substituents at the 2-position of 2-methoxyestradiol on cytotoxicity in human cancer cell cultures and inhibition of tubulin polymerization.
Journal of medicinal chemistry 2002;45(21):4748-54.
2002: Qiuwen Mi; Baoliang Cui; Gloria L Silva; Daniel D Lantvit; Eula Lim; Heebyung Chai; Melinda G Hollingshead; Joseph G Mayo; A Douglas Kinghorn; John M Pezzuto
Pervilleines B and C, new tropane alkaloid aromatic esters that reverse the multidrug-resistance in the hollow fiber assay.
Cancer letters 2002;184(1):13-20.
2002: Maria V Papadopoulou; Ming Ji; William D Bloomer; Melinda G Hollingshead
Enhancement of the antitumor effect of cyclophosphamide with the hypoxia-selective cytotoxin NLCQ-1 against murine tumors and human xenografts.
Journal of experimental therapeutics & oncology 2002;2(5):298-305.
2002: Qiuwen Mi; Daniel D Lantvit; Eulenia Reyes-Lim; Heebyung Chai; Weimin Zhao; Ik-Soo Lee; Sergio R Peraza-Sánchez; Olipa Ngassapa; Leonardus B S Kardono; Soedarsono Riswan; Melinda G Hollingshead; Joseph G Mayo; Norman R Farnsworth; Patrick Jonas; A Douglas Kinghorn; John M Pezzuto
Evaluation of the potential cancer chemotherapeutic efficacy of natural product isolates employing in vivo hollow fiber tests.
Journal of natural products 2002;65(6):842-50.
2002: Muthusamy Jayaraman; Brian M Fox; Melinda G Hollingshead; Glenda Kohlhagen; Yves Pommier; Mark Cushman
Synthesis of new dihydroindeno[1,2-c]isoquinoline and indenoisoquinolinium chloride topoisomerase I inhibitors having high in vivo anticancer activity in the hollow fiber animal model.
Journal of medicinal chemistry 2002;45(1):242-9.
2001: John Irwin Johnson; S Decker; Daniel W Zaharevitz; Lawrence V Rubinstein; J M Venditti; S Schepartz; S Kalyandrug; Michaele Christian; Arbuck Susan; Melinda G Hollingshead; Edward A Sausville
Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials.
British journal of cancer 2001;84(10):1424-31.
2001: Qiuwen Mi; Baoliang Cui; Gloria L Silva; Daniel D Lantvit; Eula Lim; Heebyung Chai; M You; Melinda G Hollingshead; Joseph G Mayo; A Douglas Kinghorn; John M Pezzuto
Pervilleine A, a novel tropane alkaloid that reverses the multidrug-resistance phenotype.
Cancer research 2001;61(10):4030-7.
2001: Susan D Mertins; Timothy G Myers; Melinda G Hollingshead; D Dykes; E Bodde; P Tsai; C A Jefferis; R Gupta; W Marston Linehan; Michael C Alley; Susan E Bates
Screening for and identification of novel agents directed at renal cell carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(3):620-33.
2001: Lloyd T Lam; Oxana Pickeral; A C Peng; Andreas Rosenwald; Elaine M Hurt; Jennifer Giltnane; L M Averett; Hong Zhao; R Eric Davis; M Sathyamoorthy; L M Wahl; E D Harris; J A Mikovits; Anne Monks; Melinda G Hollingshead; Edward A Sausville; Louis M Staudt
Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol.
Genome biology 2001;2(10):RESEARCH0041.
1999: Ze-Qi Xu; Melinda G Hollingshead; Suzanne D Borgel; C Elder; A Khilevich; Michael T Flavin
In vivo anti-HIV activity of (+)-calanolide A in the hollow fiber mouse model.
Bioorganic & medicinal chemistry letters 1999;9(2):133-8.
1998: A B Argade; R Devraj; JA Vroman; R D Haugwitz; Melinda G Hollingshead; Mark Cushman
Design and synthesis of brefeldin A sulfide derivatives as prodrug candidates with enhanced aqueous solubilities.
Journal of medicinal chemistry 1998;41(18):3337-46.
1998: O M Zack Howard; J J Oppenheim; Melinda G Hollingshead; Joseph M Covey; James C Bigelow; J J McCormack; Robert W Buckheit; DJ Clanton; Jim A Turpin; William G Rice
Inhibition of in vitro and in vivo HIV replication by a distamycin analogue that interferes with chemokine receptor function: a candidate for chemotherapeutic and microbicidal application.
Journal of medicinal chemistry 1998;41(13):2184-93.
1998: Jim A Turpin; Robert W Buckheit; D Derse; Melinda G Hollingshead; K Williamson; C Palamone; MC Osterling; S A Hill; L Graham; CA Schaeffer; M Bu; M Huang; Wieslaw Cholody; Christopher J Michejda; William G Rice
Inhibition of acute-, latent-, and chronic-phase human immunodeficiency virus type 1 (HIV-1) replication by a bistriazoloacridone analog that selectively inhibits HIV-1 transcription.
Antimicrobial agents and chemotherapy 1998;42(3):487-94.
1997: Daniela Marcantonio; Lawrence Panasci; Melinda G Hollingshead; M C Alley; R F Camalier; Edward A Sausville; D J Dykes; CA Carter; L Malspeis
2-Chloroethyl-3-sarcosinamide-1-nitrosourea, a novel chloroethylnitrosourea analogue with enhanced antitumor activity against human glioma xenografts.
Cancer research 1997;57(18):3895-8.
1997: Robert W Buckheit; Melinda G Hollingshead; S Stinson; V Fliakas-Boltz; Luke A Pallansch; J Roberson; W Decker; C Elder; Suzanne D Borgel; Carrie A Bonomi; R Shores; T Siford; L Malspeis; JP Bader
Efficacy, pharmacokinetics, and in vivo antiviral activity of UC781, a highly potent, orally bioavailable nonnucleoside reverse transcriptase inhibitor of HIV type 1.
AIDS research and human retroviruses 1997;13(9):789-96.
1997: José M P Freije; JA Lawrence; Melinda G Hollingshead; Abel De La Rosa; Ven L Narayanan; M Grever; Edward A Sausville; KD Paull; Patricia S Steeg
Identification of compounds with preferential inhibitory activity against low-Nm23-expressing human breast carcinoma and melanoma cell lines.
Nature medicine 1997;3(4):395-401.
1997: Angelika Burger; Gurmeet Kaur; Melinda G Hollingshead; RT Fischer; K Nagashima; L Malspeis; KIMBERLY DUNCAN; Edward A Sausville
Antiproliferative activity in vitro and in vivo of the spicamycin analogue KRN5500 with altered glycoprotein expression in vitro.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(3):455-63.
1996: E Lucile White; L Westbrook; Melinda G Hollingshead; W M Shannon
Optimization of the reverse transcriptase assay for the detection of viral burden in mice infected with Rauscher murine leukemia virus.
Journal of virological methods 1996;62(1):63-70.
1995: Melinda G Hollingshead; J Roberson; W Decker; Robert W Buckheit; C Elder; L Malspeis; J Mayo; Michael R Grever
In vivo drug screening applications of HIV-infected cells cultivated within hollow fibers in two physiologic compartments of mice.
Antiviral research 1995;28(3):265-79.
1995: L B Allen; D C Quenelle; L Westbrook; B A Taylor; Mark Prichard; A D Brazier; Melinda G Hollingshead; W M Shannon
In vitro and in vivo enhancement of ddI activity against Rauscher murine leukemia virus by ribavirin.
Antiviral research 1995;27(3):317-23.
1995: Melinda G Hollingshead; M C Alley; R F Camalier; B J Abbott; J G Mayo; L Malspeis; M R Grever
In vivo cultivation of tumor cells in hollow fibers.
Life sciences 1995;57(2):131-41.
1994: J J Casciari; Melinda G Hollingshead; M C Alley; J G Mayo; L Malspeis; S Miyauchi; Michael R Grever; John N Weinstein
Growth and chemotherapeutic response of cells in a hollow-fiber in vitro solid tumor model.
Journal of the National Cancer Institute 1994;86(24):1846-52.
1993: Robert W Buckheit; J Germany-Decker; Melinda G Hollingshead; L B Allen; W M Shannon; P A Janssen; M A Chirigos
Differential antiviral activity of two TIBO derivatives against the human immunodeficiency and murine leukemia viruses alone and in combination with other anti-HIV agents.
AIDS research and human retroviruses 1993;9(11):1097-106.
1993: Robert W Buckheit; Melinda G Hollingshead; J Germany-Decker; E Lucile White; James B McMahon; L B Allen; L J Ross; W D Decker; L Westbrook; W M Shannon
Thiazolobenzimidazole: biological and biochemical anti-retroviral activity of a new nonnucleoside reverse transcriptase inhibitor.
Antiviral research 1993;21(3):247-65.
1992: B Gabrielsen; T P Monath; J W Huggins; D F Kefauver; George R Pettit; G Groszek; Melinda G Hollingshead; J J Kirsi; W M Shannon; E M Schubert
Antiviral (RNA) activity of selected Amaryllidaceae isoquinoline constituents and synthesis of related substances.
Journal of natural products 1992;55(11):1569-81.
1992: Melinda G Hollingshead; L Westbrook; M J Ross; J Bailey; K J Qualls; L B Allen
An ELISA system for evaluating antiretroviral activity against Rauscher murine leukemia virus.
Antiviral research 1992;18(3-4):267-74.
1992: D J Clanton; R A Moran; James B McMahon; O S Weislow; Robert W Buckheit; Melinda G Hollingshead; Vincenzo Ciminale; Barbara K Felber; G N Pavlakis; JP Bader
Sulfonic acid dyes: inhibition of the human immunodeficiency virus and mechanism of action.
Journal of acquired immune deficiency syndromes 1992;5(8):771-81.
1992: L B Allen; S X Li; G Arnett; B Toyer; W M Shannon; Melinda G Hollingshead
Novel method for evaluating antiviral drugs against human cytomegalovirus in mice.
Antimicrobial agents and chemotherapy 1992;36(1):206-8.
1989: C K Tseng; Victor E Marquez; RW Fuller; B M Goldstein; D R Haines; H McPherson; J L Parsons; W M Shannon; G Arnett; Melinda G Hollingshead
Synthesis of 3-deazaneplanocin A, a powerful inhibitor of S-adenosylhomocysteine hydrolase with potent and selective in vitro and in vivo antiviral activities.
Journal of medicinal chemistry 1989;32(7):1442-6.

Register to see more

Copyright © 2011 Elsevier Inc. All rights reserved.